Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
Publication/Presentation Date
12-13-2018
Volume
132
Issue
24
First Page
2608
Last Page
2612
ISSN
1528-0020
Published In/Presented At
Sklavenitis-Pistofidis, R., Capelletti, M., Liu, C. J., Reidy, M., Zavidij, O., Huynh, D., Henrick, P., Savell, A., Reyes, K., Rivotto, B., Bustoros, M., Perilla-Glen, A., Trippa, L., Castillo, J. J., Treon, S. P., & Ghobrial, I. M. (2018). Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood, 132(24), 2608–2612. https://doi.org/10.1182/blood-2018-07-863241
Disciplines
Medicine and Health Sciences
PubMedID
30366921
Department(s)
Fellows and Residents
Document Type
Article
COinS